FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018872942> ?p ?o ?g. }

• W2018872942 endingPage "813" @default.
• W2018872942 startingPage "801" @default.
• W2018872942 abstract "Background Previously, patients with end-stage renal disease (ESRD) with uncontrolled hyperparathyroidism had few options other than parathyroidectomy, which was reserved for patients refractory to medical therapy. Newer calcimimetic agents, such as cinacalcet, may be an alternative, but raise the possibility of indefinite medical treatment that also would increase costs. Study Design Cost utility analysis. Setting & Population Base case consisted of prevalent adult US patients with ESRD refractory to management with standard medical therapy. Characteristics were obtained from patients who underwent parathyroidectomy in 2001, and, for purposes of comparison, patients in whom cinacalcet was used were assigned similar characteristics. All data came from preexisting literature and trials or from US Renal Data System analysis files. Intervention Use of cinacalcet hydrochloride versus parathyroidectomy. Perspective & Time Frame Medicare and societal costs and quality-adjusted life-years from the date of parathyroidectomy or use of cinacalcet followed up for 2 years, respectively. Model & Outcomes Primary outcomes were cost (measured in US dollars) and cost utility measured using cost per quality-adjusted life-years. Results At base-case surgical and drug costs, surgical and drug success rates, complication rates/costs, and benefit from correction of hyperparathyroidism, parathyroidectomy was found to be both less expensive and more cost-effective at 7.25 ± 0.25 months. Parathyroidectomy became more cost-effective at 15.28 to 16.32 months at the upper limit of sensitivity analysis, when drug/surgical costs and success/complication rates/costs were maximally weighted to favor cinacalcet-based medical therapy. Limitations We assumed current costs of both cinacalcet and parathyroidectomy and assumed cinacalcet use would be indefinite. Conclusions For patients with ESRD with uncontrolled hyperparathyroidism who are good candidates for either drug therapy or surgery, cinacalcet hydrochloride is the most cost-effective modality if the patient is to remain on dialysis therapy for 7.25 ± 0.25 months. Cinacalcet may be more optimal if used in patients who have high risk of mortality or who would expect to receive a kidney transplant quickly. For other subgroups, parathyroidectomy dominated. Previously, patients with end-stage renal disease (ESRD) with uncontrolled hyperparathyroidism had few options other than parathyroidectomy, which was reserved for patients refractory to medical therapy. Newer calcimimetic agents, such as cinacalcet, may be an alternative, but raise the possibility of indefinite medical treatment that also would increase costs. Cost utility analysis. Base case consisted of prevalent adult US patients with ESRD refractory to management with standard medical therapy. Characteristics were obtained from patients who underwent parathyroidectomy in 2001, and, for purposes of comparison, patients in whom cinacalcet was used were assigned similar characteristics. All data came from preexisting literature and trials or from US Renal Data System analysis files. Use of cinacalcet hydrochloride versus parathyroidectomy. Medicare and societal costs and quality-adjusted life-years from the date of parathyroidectomy or use of cinacalcet followed up for 2 years, respectively. Primary outcomes were cost (measured in US dollars) and cost utility measured using cost per quality-adjusted life-years. At base-case surgical and drug costs, surgical and drug success rates, complication rates/costs, and benefit from correction of hyperparathyroidism, parathyroidectomy was found to be both less expensive and more cost-effective at 7.25 ± 0.25 months. Parathyroidectomy became more cost-effective at 15.28 to 16.32 months at the upper limit of sensitivity analysis, when drug/surgical costs and success/complication rates/costs were maximally weighted to favor cinacalcet-based medical therapy. We assumed current costs of both cinacalcet and parathyroidectomy and assumed cinacalcet use would be indefinite. For patients with ESRD with uncontrolled hyperparathyroidism who are good candidates for either drug therapy or surgery, cinacalcet hydrochloride is the most cost-effective modality if the patient is to remain on dialysis therapy for 7.25 ± 0.25 months. Cinacalcet may be more optimal if used in patients who have high risk of mortality or who would expect to receive a kidney transplant quickly. For other subgroups, parathyroidectomy dominated." @default.
• W2018872942 created "2016-06-24" @default.
• W2018872942 creator A5024725543 @default.
• W2018872942 creator A5036690508 @default.
• W2018872942 creator A5042888539 @default.
• W2018872942 creator A5045383541 @default.
• W2018872942 creator A5057641292 @default.
• W2018872942 creator A5061745300 @default.
• W2018872942 creator A5065597631 @default.
• W2018872942 creator A5075301096 @default.
• W2018872942 creator A5083985641 @default.
• W2018872942 date "2007-06-01" @default.
• W2018872942 modified "2023-10-11" @default.
• W2018872942 title "Parathyroidectomy Versus Cinacalcet Hydrochloride–Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis" @default.
• W2018872942 cites W178047496 @default.
• W2018872942 cites W1963611706 @default.
• W2018872942 cites W1964423382 @default.
• W2018872942 cites W1969646860 @default.
• W2018872942 cites W1971654026 @default.
• W2018872942 cites W1973835767 @default.
• W2018872942 cites W1975747275 @default.
• W2018872942 cites W1981066436 @default.
• W2018872942 cites W1999789157 @default.
• W2018872942 cites W2011587556 @default.
• W2018872942 cites W2013270989 @default.
• W2018872942 cites W2013826249 @default.
• W2018872942 cites W2018090960 @default.
• W2018872942 cites W2041115079 @default.
• W2018872942 cites W2044501935 @default.
• W2018872942 cites W2047958578 @default.
• W2018872942 cites W2054323843 @default.
• W2018872942 cites W2058327606 @default.
• W2018872942 cites W2082365635 @default.
• W2018872942 cites W2094710838 @default.
• W2018872942 cites W2101639600 @default.
• W2018872942 cites W2119697745 @default.
• W2018872942 cites W2119786316 @default.
• W2018872942 cites W2121613126 @default.
• W2018872942 cites W2126830988 @default.
• W2018872942 cites W2142190057 @default.
• W2018872942 cites W2152542082 @default.
• W2018872942 cites W2161980688 @default.
• W2018872942 cites W2162714394 @default.
• W2018872942 cites W2167189872 @default.
• W2018872942 cites W4312547664 @default.
• W2018872942 doi "https://doi.org/10.1053/j.ajkd.2007.03.009" @default.
• W2018872942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17533023" @default.
• W2018872942 hasPublicationYear "2007" @default.
• W2018872942 type Work @default.
• W2018872942 sameAs 2018872942 @default.
• W2018872942 citedByCount "108" @default.
• W2018872942 countsByYear W20188729422012 @default.
• W2018872942 countsByYear W20188729422013 @default.
• W2018872942 countsByYear W20188729422014 @default.
• W2018872942 countsByYear W20188729422015 @default.
• W2018872942 countsByYear W20188729422016 @default.
• W2018872942 countsByYear W20188729422017 @default.
• W2018872942 countsByYear W20188729422018 @default.
• W2018872942 countsByYear W20188729422019 @default.
• W2018872942 countsByYear W20188729422020 @default.
• W2018872942 countsByYear W20188729422021 @default.
• W2018872942 countsByYear W20188729422022 @default.
• W2018872942 countsByYear W20188729422023 @default.
• W2018872942 crossrefType "journal-article" @default.
• W2018872942 hasAuthorship W2018872942A5024725543 @default.
• W2018872942 hasAuthorship W2018872942A5036690508 @default.
• W2018872942 hasAuthorship W2018872942A5042888539 @default.
• W2018872942 hasAuthorship W2018872942A5045383541 @default.
• W2018872942 hasAuthorship W2018872942A5057641292 @default.
• W2018872942 hasAuthorship W2018872942A5061745300 @default.
• W2018872942 hasAuthorship W2018872942A5065597631 @default.
• W2018872942 hasAuthorship W2018872942A5075301096 @default.
• W2018872942 hasAuthorship W2018872942A5083985641 @default.
• W2018872942 hasConcept C112930515 @default.
• W2018872942 hasConcept C126322002 @default.
• W2018872942 hasConcept C126894567 @default.
• W2018872942 hasConcept C141071460 @default.
• W2018872942 hasConcept C2775945674 @default.
• W2018872942 hasConcept C2777645128 @default.
• W2018872942 hasConcept C2778838027 @default.
• W2018872942 hasConcept C2780280601 @default.
• W2018872942 hasConcept C2780534505 @default.
• W2018872942 hasConcept C2781208988 @default.
• W2018872942 hasConcept C2908647359 @default.
• W2018872942 hasConcept C3019080777 @default.
• W2018872942 hasConcept C519063684 @default.
• W2018872942 hasConcept C64332521 @default.
• W2018872942 hasConcept C71924100 @default.
• W2018872942 hasConcept C99454951 @default.
• W2018872942 hasConceptScore W2018872942C112930515 @default.
• W2018872942 hasConceptScore W2018872942C126322002 @default.
• W2018872942 hasConceptScore W2018872942C126894567 @default.
• W2018872942 hasConceptScore W2018872942C141071460 @default.
• W2018872942 hasConceptScore W2018872942C2775945674 @default.
• W2018872942 hasConceptScore W2018872942C2777645128 @default.
• W2018872942 hasConceptScore W2018872942C2778838027 @default.
• W2018872942 hasConceptScore W2018872942C2780280601 @default.
• W2018872942 hasConceptScore W2018872942C2780534505 @default.

• next